Comparative folate metabolism in humans and malaria parasites (part I): Pointers for malaria treatment from cancer chemotherapy

Alexis Nzila; Steve A. Ward; Kevin Marsh; Paul F G Sims; John E. Hyde

doi:10.1016/j.pt.2005.04.002

Comparative folate metabolism in humans and malaria parasites (part I): Pointers for malaria treatment from cancer chemotherapy

Alexis Nzila, Steve A. Ward, Kevin Marsh, Paul F G Sims, John E. Hyde

Research output: Contribution to journal › Article › peer-review

Abstract

New inhibitors are urgently needed to overcome the burgeoning problem of drug resistance in the treatment of Plasmodium falciparum infection. Targeting the folate pathway has proved to be a powerful strategy for drug development against rapidly multiplying systems such as cancer cells and microorganisms. Antifolates have long been used for malaria treatment but, despite their success, much less is known about parasite folate metabolism than about that of the human host. In this article, we focus on folate enzymes used clinically as anticancer drug targets, in addition to those that have potential to be used as drug targets, for which there are inhibitors at various stages of development. We discuss how this information could lead to the identification of new targets in malaria parasites. © 2005 Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	292-298
Number of pages	6
Journal	Trends in parasitology
Volume	21
Issue number	6
DOIs	https://doi.org/10.1016/j.pt.2005.04.002
Publication status	Published - Jun 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.pt.2005.04.002

Cite this

@article{f10ba7afc1f64b8bb6fb6b8ff2359883,

title = "Comparative folate metabolism in humans and malaria parasites (part I): Pointers for malaria treatment from cancer chemotherapy",

abstract = "New inhibitors are urgently needed to overcome the burgeoning problem of drug resistance in the treatment of Plasmodium falciparum infection. Targeting the folate pathway has proved to be a powerful strategy for drug development against rapidly multiplying systems such as cancer cells and microorganisms. Antifolates have long been used for malaria treatment but, despite their success, much less is known about parasite folate metabolism than about that of the human host. In this article, we focus on folate enzymes used clinically as anticancer drug targets, in addition to those that have potential to be used as drug targets, for which there are inhibitors at various stages of development. We discuss how this information could lead to the identification of new targets in malaria parasites. {\textcopyright} 2005 Elsevier Ltd. All rights reserved.",

author = "Alexis Nzila and Ward, {Steve A.} and Kevin Marsh and Sims, {Paul F G} and Hyde, {John E.}",

year = "2005",

month = jun,

doi = "10.1016/j.pt.2005.04.002",

language = "English",

volume = "21",

pages = "292--298",

journal = "Trends in parasitology",

issn = "1471-4922",

publisher = "Elsevier BV",

number = "6",

}

TY - JOUR

T1 - Comparative folate metabolism in humans and malaria parasites (part I): Pointers for malaria treatment from cancer chemotherapy

AU - Nzila, Alexis

AU - Ward, Steve A.

AU - Marsh, Kevin

AU - Sims, Paul F G

AU - Hyde, John E.

PY - 2005/6

Y1 - 2005/6

N2 - New inhibitors are urgently needed to overcome the burgeoning problem of drug resistance in the treatment of Plasmodium falciparum infection. Targeting the folate pathway has proved to be a powerful strategy for drug development against rapidly multiplying systems such as cancer cells and microorganisms. Antifolates have long been used for malaria treatment but, despite their success, much less is known about parasite folate metabolism than about that of the human host. In this article, we focus on folate enzymes used clinically as anticancer drug targets, in addition to those that have potential to be used as drug targets, for which there are inhibitors at various stages of development. We discuss how this information could lead to the identification of new targets in malaria parasites. © 2005 Elsevier Ltd. All rights reserved.

AB - New inhibitors are urgently needed to overcome the burgeoning problem of drug resistance in the treatment of Plasmodium falciparum infection. Targeting the folate pathway has proved to be a powerful strategy for drug development against rapidly multiplying systems such as cancer cells and microorganisms. Antifolates have long been used for malaria treatment but, despite their success, much less is known about parasite folate metabolism than about that of the human host. In this article, we focus on folate enzymes used clinically as anticancer drug targets, in addition to those that have potential to be used as drug targets, for which there are inhibitors at various stages of development. We discuss how this information could lead to the identification of new targets in malaria parasites. © 2005 Elsevier Ltd. All rights reserved.

U2 - 10.1016/j.pt.2005.04.002

DO - 10.1016/j.pt.2005.04.002

M3 - Article

C2 - 15922251

SN - 1471-4922

VL - 21

SP - 292

EP - 298

JO - Trends in parasitology

JF - Trends in parasitology

IS - 6

ER -

Comparative folate metabolism in humans and malaria parasites (part I): Pointers for malaria treatment from cancer chemotherapy

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this